Edward L. Schwartz

Medicine

• Home
• Expert Overview
• Profile
• Publications
• Grants
• Similar Experts
• Journals
• Trends
• Institutional Network
• Coauthor Network
• Research Network

Edward L. Schwartz

• Departments
  Medicine
  
  

718-430-8864

See Einstein Faculty Profile

Help us refine your profile

This is a list of publications by this researcher, listed chronologically starting with the most recent first. New publications appear in this list weekly. The source of publications and 'cited by' data for this application is Scopus.

  Select All    |   Export

• 1.

  2010

  Giordano Pula; Elena Garonna; Warwick B. Dunn; Michio Hirano; Giuseppe Pizzorno; Michelangelo Campanella; Edward L. Schwartz; Mahmoud H. El Kouni; Caroline P.D. Wheeler-Jones

  Paracrine stimulation of endothelial cell motility and angiogenesis by platelet-derived deoxyribose-1-phosphate

  Arteriosclerosis, Thrombosis, and Vascular Biology. 2010;30(12):2631-2638.
  5

• 2.

  2009

  Nava Dalyot-Herman; Fernando Delgado-Lopez; David A. Gewirtz; John T. Gupton; Edward L. Schwartz

  Interference with endothelial cell function by JG-03-14, an agent that binds to the colchicine site on microtubules

  Biochemical Pharmacology. 2009;78(9):1167-1177.
  5

• 3.

  2009

  Haiyan Lu; Robert S. Klein; Edward L. Schwartz

  Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5- chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap

  Clinical Cancer Research. 2009;15(16):5136-5144.
  9

• 4.

  2009

  Edward L. Schwartz

  Antivascular actions of microtubule-binding drugs

  Clinical Cancer Research. 2009;15(8):2594-2601.
  60

• 5.

  2006

  Janice Murtagh; Haiyan Lu; Edward L. Schwartz

  Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation

  Cancer Research. 2006;66(16):8192-8199.
  21

• 6.

  2006

  Haiyan Lu; Janice Murtagh; Edward L. Schwartz

  The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (Taxotere)

  Molecular Pharmacology. 2006;69(4):1207-1215.
  26

• 7.

  2003

  John M. Mariadason; Diego Arango; Qiuhu Shi; Andrew J. Wilson; Georgia A. Corner; Courtney Nicholas; Maria J. Aranes; Martin Lesser; Edward L. Schwartz; Leonard H. Augenlicht

  Gene Expression Profiling-Based Prediction of Response of Colon Carcinoma Cells to 5-Fluorouracil and Camptothecin

  Cancer Research. 2003;63(24):8791-8812.
  135

• 8.

  2003

  Geng Hui Zhu; Edward L. Schwartz

  Expression of the Angiogenic Factor Thymidine Phosphorylase in THP-1 Monocytes: Induction by Autocrine Tumor Necrosis Factor-α and Inhibition by Aspirin

  Molecular Pharmacology. 2003;64(5):1251-1258.
  18

• 9.

  2003

  Kylie A. Hotchkiss; Anthony W. Ashton; Edward L. Schwartz

  Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins α₅β₁ and α_vβ₃

  Journal of Biological Chemistry. 2003;278(21):19272-19279.
  40

• 10.

  2003

  Kylie A. Hotchkiss; Anthony W. Ashton; Robert S. Klein; Michelle L. Lenzi; Geng Hui Zhu; Edward L. Schwartz

  Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration

  Cancer Research. 2003;63(2):527-533.
  64

• 11.

  2002

  Geng Hui Zhu; Michelle Lenzi; Edward L. Schwartz

  The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells

  Oncogene. 2002;21(55):8477-8485.
  44

• 12.

  2002

  Kylie A Hotchkiss; Anthony W Ashton; Radma Mahmood; Robert G Russell; Joseph A Sparano; Edward L Schwartz

  Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.

  Molecular cancer therapeutics. 2002;1(13):1191-1200.
  109

• 13.

  2001

  Robert S. Klein; Michelle Lenzi; Timothy H. Lim; Kylie A. Hotchkiss; Phyllis Wilson; Edward L. Schwartz

  Novel 6-substituted uracil analogs as inhibitors of the angiogenic actions of thymidine phosphorylase

  Biochemical Pharmacology. 2001;62(9):1257-1263.
  40

• 14.

  1999

  Scott Wadler; Edward L. Schwartz; Patrick Anderson; Carolyn D. Runowicz; Linus Chuang; Giuseppe Del Priore; Howard Hochster; Gary Goldberg; Abbie Fields; et al.

  Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer

  Cancer Journal from Scientific American. 1999;5(3):165-170.
  6

• 15.

  1998

  Ralf Metzger; Kathleen Danenberg; C. Gail Leichman; Dennis Salonga; Edward L. Schwartz; Scott Wadler; Heinz-Josef Lenz; Susan Groshen; Lawrence Leichman; et al.

  High basal level gene expression of thymidine phosphorylase (platelet- derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil

  Clinical Cancer Research. 1998;4(10):2371-2376.
  202

• 16.

  1998

  Scott Wadler; Robert Horowitz; Hong-Yang Zhang; Edward L. Schwartz

  Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G₁/S transition state enzyme, in p53-mutated cells

  Biochemical Pharmacology. 1998;55(9):1353-1360.
  19

• 17.

  1998

  Edward L. Schwartz; Emily Wan; Fu-Shen Wang; Nicole Baptiste

  Regulation of expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cells

  Cancer Research. 1998;58(7):1551-1557.
  38

• 18.

  1997

  Robert W. Horowitz; Hong-yang Zhang; Edward L. Schwartz; Robert D. Ladner; Scott Wadler

  Measurement of deoxyuridine triphosphate and thymidine triphosphate in the extracts of thymidylate Synthase-Inhibited cells using a modified DNA polymerase assay

  Biochemical Pharmacology. 1997;54(5):635-638.
  19

• 19.

  1997

  Robert W. Horowitz; Barbara G. Heerdt; Xioaping Hu; Edward L. Schwartz; Scott Wadler

  Combination therapy with 5-fluorouracil and IFN-α2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells

  Clinical Cancer Research. 1997;3(8):1317-1322.
  13

• 20.

  1997

  Della Makower; Scott Wadler; Hilda Haynes; Edward L. Schwartz

  Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo

  Clinical Cancer Research. 1997;3(6):923-929.
  30

• 21.

  1997

  Scott Wadler; Edward L. Schwartz; Hilda Haynes; Ronalde Rameau; Astrid Quish; John Mandeli; Robert Gallagher; Steven Hallam; Abbie Fields; Gary Goldberg; et al.

  All-trans retinoic acid and interferon-α-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: Clinical and pharmacokinetic studies

  Cancer. 1997;79(8):1574-1580.
  18

• 22.

  1997

  Kevin P. O'Boyle; Yuexian Wang; Edward L. Schwartz; Donna Lee Regl; Avi Einzig; Janice P. Dutcher; Peter H. Wiernik; Susan Band Horwitz

  Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids

  Cancer. 1997;79(5):1022-1030.
  14

• 23.

  1997

  S. Wadler; E.L. Schwartz; R. Herrmann

  Role of interferon as a modulator of fluoropyrimidines: Reply to a recent editorial [1]

  Annals of Oncology. 1997;8(2):139-141.
  0

• 24.

  1997

  Andrea N. Leaf; Donna Neuberg; Edward L. Schwartz; Scott Wadler; Paul S. Ritch; Janice P. Dutcher; George L. Adams

  An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390)

  Investigational New Drugs. 1997;15(2):165-172.
  6

• 25.

  1996

  Scott Wadler; Robert Horowitz; Xun Mao; Edward L. Schwartz

  Effect of interferon on 5-fluououracil-induced perturbations in pools of deoxynucleotide triphosphates and DNA strand breaks

  Cancer Chemotherapy and Pharmacology. 1996;38(6):529-535.
  22

• 26.

  1996

  Scott Wadler; Robert Horowitz; Jie Rao; Xun Mao; Kathie Schlesinger; Edward L. Schwartz

  Interferon augments the cytotoxicity of hydroxyurea without enhancing its activity against the M2 subunit of ribonucleotide reductase: Effects in wild-type and resistant human colon cancer cells

  Cancer Chemotherapy and Pharmacology. 1996;38(6):522-528.
  15

• 27.

  1996

  J.A. Sparano; P.H. Wiernik; X. Hu; C. Sarta; E.L. Schwartz; R. Soeiro; D.H. Henry; B. Mason; H. Ratech; J.P. Dutcher

  Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus- associated non-Hodgkin's lymphoma

  Journal of Clinical Oncology. 1996;14(11):3026-3035.
  94

• 28.

  1995

  Edward L. Schwartz; Steven Hallam; Robert E. Gallagher; Peter H. Wiernik

  Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia

  Biochemical Pharmacology. 1995;50(7):923-928.
  55

• 29.

  1995

  R. Horowitz; E.L. Schwartz; S. Wadler

  Modulation of 5-fluorouracil by interferon: A review of potential cellular targets

  Medical Oncology. 1995;12(1):3-8.
  3

• 30.

  1995

  Leslie Oleksowicz; Zbigniew Mrowiec; Edward Schwartz; Manoochehr Khorshidi; Janice P. Dutcher; Elena Puszkin

  Characterization of tumor-induced platelet aggregation: The role of immunorelated gpIb and gpIIb/IIIa expression by MCF-7 breast cancer cells

  Thrombosis Research. 1995;79(3):261-274.
  50

• 31.

  1995

  E.L. Schwartz; N. Baptiste; S. Wadler; D. Makower

  Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil

  Journal of Biological Chemistry. 1995;270(32):19073-19077.
  94

• 32.

  1995

  S. Wadler; E.L. Schwartz; N.E. Kemeny

  Chemotherapy for colorectal carcinoma: Observations regarding recent clinical trials using biochemical modulation [1]

  Journal of Clinical Oncology. 1995;13(10):2676-2677.
  8

• 33.

  1995

  E.L. Schwartz; N. Baptiste; S. Megati; S. Wadler; B.A. Otter

  5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression

  Cancer Research. 1995;55(16):3543-3550.
  38

• 34.

  1994

  S. Wadler; E.L. Schwartz

  Biologic agents as biochemical modulators: Pharmacologic basis for the interaction of cytotoxic chemotherapeutic drugs and interferon

  Cancer Chemotherapy and Pharmacology. 1994;35(1):21-30.
  7

• 35.

  1994

  E.L. Schwartz; N. Baptiste; C.J. O'Connor; S. Wadler; B.A. Otter

  Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase

  Cancer Research. 1994;54(6):1472-1478.
  48

• 36.

  1993

  J.A. Sparano; S. Wadler; L. Liebes; N.J. Robert; E.L. Schwartz; J.P. Dutcher

  Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-α2b in patients with advanced breast cancer

  Cancer Research. 1993;53(15):3509-3512.
  5

• 37.

  1993

  J.A. Sparano; S. Wadler; R.B. Diasio; R. Zhang; Z. Lu; E.L. Schwartz; A. Einzig; P.H. Wiernik

  Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: Evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation

  Journal of Clinical Oncology. 1993;11(8):1609-1617.
  12

• 38.

  1993

  S. Wadler; X. Mao; R. Bajaj; S. Hallam; E.L. Schwartz

  N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-α-2a against human colon cancer cell lines

  Molecular Pharmacology. 1993;44(5):1070-1076.
  8

• 39.

  1993

  E.L. Schwartz; H. Chamberlin; P. Ravichander; J.A. Whitbread

  Dimethyl sulfoxide inhibits the binding of granulocyte/macrophage colony- stimulating factor and insulin to their receptors on human leukemia cells

  Cancer Research. 1993;53(5):1142-1148.
  3

• 40.

  1993

  J.A. Sparano; S. Wadler; E.L. Schwartz; R. Diasio

  Clinical and pharmacological studies of interferon and chemotherapy in gastrointestinal and breast cancer

  International Journal of Clinical Pharmacology Research. 1993;13(1):1-9.
  4

• 41.

  1993

  C. Mazurek; J.P. Dutcher; E.L. Schwartz; S. Garl; L. Benson; P.H. Wiernik

  Phase I clinical and pharmacokinetic study of menogaril (7-con-O- methylnogarol) in previously treated patients with acute leukemia

  Investigational New Drugs. 1993;11(4):313-322.
  2

• 42.

  1992

  S. Wadler; E.L. Schwartz

  Principles in the biomodulation of cytotoxic drugs by interferons

  Seminars in Oncology. 1992;19(2 SUPPL. 3):45-48.
  8

• 43.

  1992

  E.L. Schwartz; M. Hoffman; C.J. O'Connor; S. Wadler

  Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells

  Biochemical and Biophysical Research Communications. 1992;182(3):1232-1239.
  95

• 44.

  1992

  E.L. Schwartz; A.-B. Brechbuhl; P. Kahl; M.A. Miller; P.A. Selwyn; G.H. Friedland

  Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection

  Journal of Acquired Immune Deficiency Syndromes. 1992;5(6):619-626.
  45

• 45.

  1991

  E.L. Schwartz; H. Chamberlin; A.-B. Brechbuhl

  Regulation of c-myc expression by granulocyte-macrophage colony-stimulating factor in human leukemia cells

  Blood. 1991;77(12):2716-2723.
  7

• 46.

  1990

  S. Wadler; R. Wersto; V. Weinberg; D. Thompson; E.L. Schwartz

  Interaction of fluorouracil and interferon in human colon cancer cell lines: Cytotoxic and cytokinetic effects

  Cancer Research. 1990;50(18):5735-5739.
  65

• 47.

  1990

  J.A. Sparano; E.L. Schwartz; K.M. Salva; M.F. Pizzillo; S. Wadler; P.H. Wiernik

  Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer

  American Journal of Clinical Oncology: Cancer Clinical Trials. 1990;13(5):374-378.
  9

• 48.

  1990

  S. Wadler; E.L. Schwartz

  Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review

  Cancer Research. 1990;50(12):3473-3486.
  188

• 49.

  1990

  E.L. Schwartz; H. Chamberlin; A.B. Brechbuhl

  Inhibition of c-myc expression in human promyelocytic leukemia and colon adenocarcinoma cells by 6-thioguanine

  Biochemical Pharmacology. 1990;40(11):2449-2455.
  2

• 50.

  1989

  E.L. Schwartz; L.A. Nilson

  Activation of 2',5'-oligoadenylate synthetase activity on induction of HL-60 leukemia cell differentiation

  Molecular and Cellular Biology. 1989;9(9):3897-3903.
  5

• 51.

  1989

  S. Wadler; E.L. Schwartz; M. Goldman; A. Lyver; M. Rader; M. Zimmerman; L. Itri; V. Weinberg; P.H. Wiernik

  Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma

  Journal of Clinical Oncology. 1989;7(12):1769-1775.
  134

• 52.

  1989

  R.E. Gallagher; F. de Cuevillas; C.S. Chang; E.L. Schwartz

  Variable regulation of sensitivity to retinoic acid-induced differentiation in wild-type and retinoic acid-resistant HL-60 cells.

  Cancer communications. 1989;1(1):45-54.
  3

• 53.

  1988

  E.L. Schwartz; L. Nilson

  Multiple mechanisms for the inhibition of rRNA synthesis during HL-60 leukemia cell differentiation

  Journal of Cellular Physiology. 1988;136(3):526-530.
  4

• 54.

  1988

  Iraj Lalezari; Edward L. Schwartz

  Synthesis and antineoplastic activity of 5-aryl-2,3-dihydropyrrolo[2,1-b]thiazole-6,7-dimethanol 6,7-bis(isopropylcarbamates)

  Journal of Medicinal Chemistry. 1988;31(7):1427-1429.
  26

• 55.

  1988

  E.L. Schwartz; A.M. Maher

  Enhanced mitogenic responsiveness to granulocyte-macrophage colony-stimulating factor in HL-60 promyelocytic leukemia cells upon induction of differentiation

  Cancer Research. 1988;48(10):2683-2687.
  3

• 56.

  1988

  E.L. Schwartz; P.H. Wiernik

  Differentiation of leukemia cells by chemotherapeutic agents

  Journal of Clinical Pharmacology. 1988;28(9):779-794.
  0

• 57.

  1987

  P.H. Wiernik; E.L. Schwartz; J.J. Strauman; J.P. Dutcher; R.B. Lipton; E. Paietta

  Phase I clinical and pharmacokinetic study of taxol

  Cancer Research. 1987;47(9):2486-2493.
  211

• 58.

  1987

  P.H. Wiernik; E.L. Schwartz; A. Einzig; J.J. Strauman; R.B. Lipton; J.P. Dutcher

  Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma

  Journal of Clinical Oncology. 1987;5(8):1232-1239.
  147

• 59.

  1984

  K. Ishiguro; E.L. Schwartz; A.C. Sartorelli

  Characterization of the metabolic forms of 6-thioguanine responsible for cytotoxicity and induction of differentiation of HL-60 acute promyelocytic leukemia cells

  Journal of Cellular Physiology. 1984;121(2):383-390.
  8

• 60.

  1984

  E.L. Schwartz; O.C. Blair; A.C. Sartorelli

  Cell cycle events associated with the termination of proliferation by cytotoxic and differentiation-inducing actions of 6-thioguanine on HL-60 cells

  Cancer Research. 1984;44(9):3907-3910.
  1

• 61.

  1983

  Edward L. Schwartz; Anthony F. Hadfield; Alfred E. Brown; Alan C. Sartorelli

  Modification of sialic acid metabolism of murine erythroleukemia cells by analogs of N-acetylmannosamine

  BBA - Molecular Cell Research. 1983;762(4):489-497.
  6

• 62.

  1983

  Edward L. Schwartz; Kimiko Ishiguro; Alan C. Sartorelli

  Induction of leukemia cell differentiation by chemotherapeutic agents

  Advances in Enzyme Regulation. 1983;21(C):3-20.
  2

• 63.

  1983

  E.L. Schwartz; B.J. Brown; M. Nierenburg; J.C. Marsh; A.C. Sartorelli

  Evaluation of some anthracycline antibiotics in an in vivo model for studying drug-induced human leukemia cell differentiation

  Cancer Research. 1983;43(6):2725-2730.
  6

• 64.

  1982

  Alfred E. Brown; Edward L. Schwartz; Robert N. Dreyer; Alan C. Sartorelli

  Synthesis of sialoglycoconjugates during dimethylsufoxide-induced erythrodifferentiation of friend leukemia cells

  BBA - General Subjects. 1982;714(2):217-225.
  2

• 65.

  1982

  L.S. Rittmann; C.L. Jelsema; E.L. Schwartz; A.S. Tsiftsoglou; A.C. Sartorelli

  Lipid composition of Friend leukemia cells following induction of erythroid differentiation by dimethyl sulfoxide

  Journal of Cellular Physiology. 1982;110(1):50-55.
  1

• 66.

  1982

  E.L. Schwartz; A.C. Sartorelli

  Structure-activity relationships for the induction of differentiation of HL-60 human acute promyelocytic leukemia cells by anthracyclines

  Cancer Research. 1982;42(7):2651-2655.
  13

• 67.

  1981

  Chau-Der Li; Edward L. Schwartz; Sharon L. Mella; Lana S. Rittmann; Alan C. Sartorelli

  Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones

  Journal of Medicinal Chemistry. 1981;24(9):1092-1094.
  2

• 68.

  1980

  Rose J. Papac; Alfred E. Brown; Edward L. Schwartz; Alan C. Sartorelli

  Differentiation of human promyelocytic leukemia cells in vitro by 6-thioguanine

  Cancer Letters. 1980;10(1):33-38.
  4